NZ702146A - Peptides derived from viral proteins for use as immunogens and dosage reactants - Google Patents

Peptides derived from viral proteins for use as immunogens and dosage reactants

Info

Publication number
NZ702146A
NZ702146A NZ702146A NZ70214613A NZ702146A NZ 702146 A NZ702146 A NZ 702146A NZ 702146 A NZ702146 A NZ 702146A NZ 70214613 A NZ70214613 A NZ 70214613A NZ 702146 A NZ702146 A NZ 702146A
Authority
NZ
New Zealand
Prior art keywords
immunogens
reactants
dosage
viral proteins
peptides derived
Prior art date
Application number
NZ702146A
Other languages
English (en)
Inventor
Birger Sørensen
Arnt Ove Hovden
Maja Sommerfelt Grønvold
Mats Ökvist
Original Assignee
Bionor Immuno As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionor Immuno As filed Critical Bionor Immuno As
Publication of NZ702146A publication Critical patent/NZ702146A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
NZ702146A 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants NZ702146A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656256P 2012-06-06 2012-06-06
PCT/EP2013/061751 WO2013182661A1 (en) 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants

Publications (1)

Publication Number Publication Date
NZ702146A true NZ702146A (en) 2016-11-25

Family

ID=48577073

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ702146A NZ702146A (en) 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants

Country Status (15)

Country Link
US (1) US10501499B2 (enExample)
EP (1) EP2859011B1 (enExample)
JP (1) JP6310909B2 (enExample)
KR (1) KR20150018870A (enExample)
CN (1) CN104619718A (enExample)
AU (1) AU2013273482A1 (enExample)
BR (1) BR112014030466A2 (enExample)
CA (1) CA2874923C (enExample)
EA (1) EA201492262A1 (enExample)
HK (1) HK1207871A1 (enExample)
IL (1) IL235891A0 (enExample)
IN (1) IN2014KN02769A (enExample)
MX (1) MX2014014683A (enExample)
NZ (1) NZ702146A (enExample)
WO (1) WO2013182661A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121291A2 (en) * 2013-02-04 2014-08-07 University Of Notre Dame Du Lac Nanoparticle drug delivery systems
AU2015312075A1 (en) 2014-09-03 2017-03-09 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3471758A1 (en) * 2016-06-20 2019-04-24 ISA Pharmaceuticals B.V Formulation of a peptide vaccine
WO2018127689A1 (en) * 2017-01-03 2018-07-12 Emergex Vaccines Holdings Ltd Universal influenza vaccine compositions
CN110548136A (zh) * 2018-05-30 2019-12-10 王美亮 汉坦病毒长肽疫苗
CN119306795A (zh) * 2019-03-25 2025-01-14 免疫功坊股份有限公司 带有金属结合区的复合多肽及其分子构建体
KR102393872B1 (ko) * 2019-08-28 2022-05-04 엠브릭스 주식회사 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도
EP4103587A1 (en) * 2020-02-14 2022-12-21 Immunor AS Corona virus vaccine
KR102707584B1 (ko) * 2020-04-02 2024-09-19 조선대학교산학협력단 코로나바이러스 감염증­１９의 진단 및 백신을 위한 재조합 뉴클레오캡시드 단백질 및 이의 용도

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
PH30906A (en) 1991-07-25 1997-12-23 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses.
MA22842A1 (fr) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
RU2160120C2 (ru) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PT735893E (pt) 1993-09-14 2009-03-06 Pharmexa Inc Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
ES2239819T3 (es) 1993-11-04 2005-10-01 Innogenetics N.V. Epitopos inmunodominantes de celulas t humanas del virus de la hepatitis c.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1995027733A1 (en) 1994-04-08 1995-10-19 The Government Of The United States Of America, Represented By The Department Of Health & Human Services Hepatitis c virus core peptide for stimulation of cytotoxic t lymphocytes and diagnosis of hcv exposure
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AU2658897A (en) 1996-03-21 1997-10-10 Epimmune, Inc. Hla-a2.1 binding peptides and their uses
ATE311463T1 (de) 1996-05-24 2005-12-15 Chiron Corp Fusionsprotein mit multiplen epitopen
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2222728T3 (es) 1998-10-05 2005-02-01 Pharmexa A/S Procedimiento de vacunacion terapeutica.
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
ATE502952T1 (de) 2000-09-01 2011-04-15 Epimmune Inc Hla-bindungspeptide und ihre anwendungszwecke
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
AU2003236728A1 (en) 2002-06-10 2003-12-22 Algonomics N.V. Method for predicting the binding affinity of mhc/peptide complexes
EP1543039B1 (en) * 2002-08-12 2011-07-13 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2008107400A1 (en) * 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
WO2011000962A2 (en) 2009-07-03 2011-01-06 Bionor Immuno As Novel therapeutic and diagnostic means
US9550811B2 (en) * 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
EA034031B1 (ru) * 2011-01-06 2019-12-20 Бионор Иммуно Ас Димерный пептид для индуцирования иммунного ответа против hiv и его применение
US8618303B2 (en) * 2011-01-07 2013-12-31 Hoffmann-La Roche Inc. Pyrrolidine derivatives

Also Published As

Publication number Publication date
JP6310909B2 (ja) 2018-04-11
EP2859011B1 (en) 2019-12-11
MX2014014683A (es) 2015-02-24
CA2874923C (en) 2021-08-31
US10501499B2 (en) 2019-12-10
WO2013182661A1 (en) 2013-12-12
CA2874923A1 (en) 2013-12-12
HK1207871A1 (en) 2016-02-12
CN104619718A (zh) 2015-05-13
EP2859011A1 (en) 2015-04-15
JP2015521206A (ja) 2015-07-27
BR112014030466A2 (pt) 2017-09-12
IL235891A0 (en) 2015-01-29
EA201492262A1 (ru) 2015-08-31
KR20150018870A (ko) 2015-02-24
US20150152140A1 (en) 2015-06-04
IN2014KN02769A (enExample) 2015-05-08
AU2013273482A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
EA201390806A1 (ru) Конструкция пептидного каркаса
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
MX2018010483A (es) Inmunogenos para vacunacion contra vih.
PH12014500557A1 (en) Methods for treating hcv
EA201591287A1 (ru) Вакцины, содержащие стабилизированные тримеры оболочки вируса иммунодефицита человека, и способы их применения
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
PH12014500369A1 (en) Influenza h5 vaccines
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112017006680A2 (pt) variantes de vírus influenza a
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
PH12014502551A1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
MX360161B (es) Proceso para preparar compuestos antiviricos.
MX2019007924A (es) Vacunas contra la influenza.
MX2014004537A (es) Vacunas para el virus del papiloma humano y metodos para su uso.
MY199945A (en) Vaccines against infectious diseases caused by positive stranded rna viruses
MX358507B (es) Antigenos vacunales quimericos contra el virus de la hepatitis c.
GB201008123D0 (en) Novel compounds
MX360137B (es) Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
PH12015500831A1 (en) Treatment of viral and infectious diseases using an inhibitor of cbp/catenin

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed